Growth inhibition of Toxoplasma gondii and Plasmodium falciparum by nanomolar concentrations of 1-hydroxy-2-dodecyl-4(1H)quinolone, a high-affinity inhibitor of alternative (type II) NADH dehydrogenases
about
The therapeutic potential of metal-based antimalarial agents: implications for the mechanism of actionFerrocene-based antimalarialsThe structure of the yeast NADH dehydrogenase (Ndi1) reveals overlapping binding sites for water- and lipid-soluble substratesStructure of the bacterial type II NADH dehydrogenase: a monotopic membrane protein with an essential role in energy generationAntibiotics in malaria therapy: which antibiotics except tetracyclines and macrolides may be used against malaria?Repurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolyticaIn vitro and in vivo activities of 1-hydroxy-2-alkyl-4(1H)quinolone derivatives against Toxoplasma gondii.Network-based assessment of the selectivity of metabolic drug targets in Plasmodium falciparum with respect to human liver metabolismArrested oocyst maturation in Plasmodium parasites lacking type II NADH:ubiquinone dehydrogenase.Type II NADH dehydrogenase of the respiratory chain of Plasmodium falciparum and its inhibitors.HDQ, a potent inhibitor of Plasmodium falciparum proliferation, binds to the quinone reduction site of the cytochrome bc1 complex.Characterization of Toxoplasma gondii glyoxalase 1 and evaluation of inhibitory effects of curcumin on the enzyme and parasite culturesA Systematic Review of In vitro and In vivo Activities of Anti-Toxoplasma Drugs and Compounds (2006-2016).Drugs in development for toxoplasmosis: advances, challenges, and current status.Functional genetics in Apicomplexa: potentials and limits.1,2-substituted 4-(1H)-quinolones: synthesis, antimalarial and antitrypanosomal activities in vitro.Two internal type II NADH dehydrogenases of Toxoplasma gondii are both required for optimal tachyzoite growth.Type II NADH dehydrogenase inhibitor 1-hydroxy-2-dodecyl-4(1H)quinolone leads to collapse of mitochondrial inner-membrane potential and ATP depletion in Toxoplasma gondii.Quantitative structure-activity relationship studies of antimalarial compounds from their calculated mathematical descriptors.A novel drug for uncomplicated malaria: targeted high throughput screening (HTS) against the type II NADH:ubiquinone oxidoreductase (PfNdh2) of Plasmodium falciparum.Mitochondrial dehydrogenases in the aerobic respiratory chain of the rodent malaria parasite Plasmodium yoelii yoelii.Ubiquinone binding site of yeast NADH dehydrogenase revealed by structures binding novel competitive- and mixed-type inhibitors.Structure of the NDH-2 - HQNO inhibited complex provides molecular insight into quinone-binding site inhibitors.Highly diverged novel subunit composition of apicomplexan F-type ATP synthase identified from Toxoplasma gondii
P2860
Q20906133-83A0E196-DC04-43E6-81B2-438002D132B5Q21032535-338E3BF9-9AC6-4EEC-9025-AE046B60EB94Q27672194-5ACB7083-6017-4CE4-9CFF-ED37EC8BE475Q27688947-F5751A47-C07E-4EB6-8F31-49141B17A970Q28076750-CA1D96D1-B1C8-4E39-992A-0289B6ABB1D8Q30487158-F09EF80F-6E1D-4F30-948A-0180EDA23683Q33558897-51EE7439-250B-4950-828B-2F21397E25A2Q34399911-DDE836B2-B7E3-4452-8E5D-6F0543682020Q35213449-582FA59B-581F-4B2A-A7AD-27C5AF02DFC4Q35576414-30F1F78B-097E-4E70-A91C-E8A45BFB7506Q36086330-93806057-B01C-4775-8407-11335D56702CQ36398100-E4D1DE4F-EE80-4885-8A4A-97DBCBB68B42Q37594988-4D5D79A8-8FC6-4AE6-93C3-2CD8E0D181D6Q37613765-5A04775C-91C7-4D95-8549-87E3D0862A56Q37873986-0D432A68-B1E4-4928-8513-8C14F0261F4AQ38957504-81BAE081-7C4F-4AAD-AD59-C6D1F03A169DQ39487936-97688AE1-42C2-48D8-BA47-710F95745009Q41374052-941AB993-D3F2-4F12-A5D1-FB03D07EDD40Q41936186-A05C2970-8D4B-4D2E-AA57-37AAD03CFF19Q45973562-94047B38-BD05-4C4A-A969-35AF9EB3450BQ46211758-8BE18032-8CA0-4B0E-8D5F-341408E06184Q48103164-13B85E99-6F39-40ED-BB1A-FFB8F65FE3A3Q52330907-AE29FA24-63A7-49F1-8B29-955EDCC86FB5Q56557856-95957BC6-0B55-4E5E-95B7-9674CCCA7293
P2860
Growth inhibition of Toxoplasma gondii and Plasmodium falciparum by nanomolar concentrations of 1-hydroxy-2-dodecyl-4(1H)quinolone, a high-affinity inhibitor of alternative (type II) NADH dehydrogenases
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Growth inhibition of Toxoplasm ...... (type II) NADH dehydrogenases
@en
Growth inhibition of Toxoplasm ...... (type II) NADH dehydrogenases
@nl
type
label
Growth inhibition of Toxoplasm ...... (type II) NADH dehydrogenases
@en
Growth inhibition of Toxoplasm ...... (type II) NADH dehydrogenases
@nl
prefLabel
Growth inhibition of Toxoplasm ...... (type II) NADH dehydrogenases
@en
Growth inhibition of Toxoplasm ...... (type II) NADH dehydrogenases
@nl
P2093
P2860
P921
P356
P1476
Growth inhibition of Toxoplasm ...... (type II) NADH dehydrogenases
@en
P2093
Ahmad Saleh
Johannes Friesen
Wolfgang Bohne
P2860
P304
P356
10.1128/AAC.00895-06
P407
P577
2007-01-22T00:00:00Z